Related
has buy call on with a target price of Rs 2500. The current market price of Zydus Wellness Ltd. is Rs 2234.85. Time period given by analyst is one year when Zydus Wellness Ltd. price can reach defined target.
Zydus Wellness Ltd., incorporated in the year 1994, is a Mid Cap company (having a market cap of Rs 14266.33 Crore) operating in FMCG sector.
Financials
For the quarter ended 30-06-2021, the company reported a Consolidated Total Income of Rs 599.97 Crore, down -1.24 % from last quarter Total Income of Rs 607.52 Crore and up 11.27 % from last year same quarter Total Income of Rs 539.19 Crore. Company reported net profit after tax of Rs 130.80 Crore in latest quarter.
Investment Rationale
The earnings estimates are largely unchanged. It models revenue / EBITDA / PAT CAGR of 11% / 19% / 35% over FY21-23E – net profit likely to grow ahead of revenue and EBITDA driven by deleveraging of balance sheet. It maintains BUY with a DCF-based unchanged target price of Rs2,500. At the target price, the stock will trade at 35x P/E multiple Mar-23E. Key downside risks are delays or failures in new product development or inability to expand distribution.
Promoter/FII Holdings
Promoters held 64.8 per cent stake in the company as of June 30, 2021, while FIIs held 17 per cent, DIIs 10.7 per cent and public and others 7.5 per cent.
Zydus Wellness Ltd., incorporated in the year 1994, is a Mid Cap company (having a market cap of Rs 14266.33 Crore) operating in FMCG sector.
Financials
For the quarter ended 30-06-2021, the company reported a Consolidated Total Income of Rs 599.97 Crore, down -1.24 % from last quarter Total Income of Rs 607.52 Crore and up 11.27 % from last year same quarter Total Income of Rs 539.19 Crore. Company reported net profit after tax of Rs 130.80 Crore in latest quarter.
Did you Know?
Stock score of Zydus Wellness Ltd moved down by 1 in a week on a 10-point scale.
View Latest Stock Report »The earnings estimates are largely unchanged. It models revenue / EBITDA / PAT CAGR of 11% / 19% / 35% over FY21-23E – net profit likely to grow ahead of revenue and EBITDA driven by deleveraging of balance sheet. It maintains BUY with a DCF-based unchanged target price of Rs2,500. At the target price, the stock will trade at 35x P/E multiple Mar-23E. Key downside risks are delays or failures in new product development or inability to expand distribution.
Promoter/FII Holdings
Promoters held 64.8 per cent stake in the company as of June 30, 2021, while FIIs held 17 per cent, DIIs 10.7 per cent and public and others 7.5 per cent.
(Disclaimer: Views and recommendations given in this section are the analysts' own and do not represent those of ETMarkets.com. Please consult your financial adviser before taking any position in the stock/s mentioned.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
